213Bi (α-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model

Cancer Research

Volumn 68, Issue 10, 2008, Pages 3873-3880

  Song, Hong ^a   Shahverdi, Karineh ^a   Huso, David L ^a   Esaias, Caroline ^a   Fox, James ^a   Liedy, Allison ^a   Zhang, Zhe ^a   Reilly, R Todd ^a   Apostolidis, Christos ^b   Morgenstern, Alfred ^b   Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOINT RESEARCH CENTRE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 213; CD20 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; RITUXIMAB;

ALPHA RADIATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CONTROLLED STUDY; DOSIMETRY; DRUG EFFICACY; HISTOPATHOLOGY; ISOTOPE LABELING; LIVER METASTASIS; MAXIMUM TOLERATED DOSE; METASTASIS; MICROMETASTASIS; MOUSE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RADIOISOTOPE DISTRIBUTION; SURVIVAL TIME; TRANSGENIC MOUSE; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CHEMISTRY; EXPERIMENTAL NEOPLASM; GENETICS; INSTRUMENTATION; KINETICS; METABOLISM; METHODOLOGY; MULTICELLULAR SPHEROID; PATHOLOGY; RAT; TIME;

ANIMALS; ANTIBODIES, MONOCLONAL; KINETICS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; RATS; RECEPTOR, ERBB-2; SPHEROIDS, CELLULAR; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 45549088490     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6308     Document Type: Article

References (33)

1. American Cancer Society Cancer facts and figures 2006 2007;17.
2. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13.
3. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
4. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women withearly breast cancer. N Engl J Med 2005;353:2747-57.
5. Abe O, Abe R, Enomoto K, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366: 2087-106.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Human-breast cancer-correlation of relapse and survival withamplification of the Her-2 Neu oncogene. Science 1987;235:177-82.
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
9. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
10. Lan KH, Lu CH, Yu DH. Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci 2005;1059:70-5.
11. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med 1998;25:1341-51.
12. 213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001;61: 2008-14.
13. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000; 60:6095-100.
14. Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834-41.
15. Huber R, Seidl C, Schmid E, et al. Locoregional α- radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-speciric monoclonal antibody. Clin Cancer Res 2003;9:3922-8S.
16. Kennel SJ, Stabin M, Yoriyaz H, Brechbiel M, Mirzadeh S. Treatment of lung tumor colonies with Y-90 targeted to blood vessels: comparison with the α-particle emitter Bi-213. Nucl Med Biol 1999;26:149-57.
17. Rizvi SMA, Qu CF, Song YJ, Raja C, Allen BJ. In vivo studies of pharmacokinetics and efficacy of bismuth-213 labeled antimelanoma monoclonal antibody 9.2.27. Cancer Biol Ther 2005;4:763-8.
18. Jurcic JG, Larson SM, Sgouros G, et al. Targeted α particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9.
19. Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: Bi-213-HuM195 (anti-CD33) in patients withleukemia. J Nucl Med 1999;40:1935-46.
20. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the Neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89: 10578-82.
21. Song H, Shahverdi K, Fox J, et al. A model of metastatic breast carcinoma for targeted α-emitter therapy modeling/dosimetry studies [abstract]. Cancer Biother Radiopharm 2004;19:518.
22. Reilly RT, Gottlieb MBC, Ercolini AM, et al. HER-2/ neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res 2000;60:3569-76.
23. Brechbiel MW, Pippin CG, Mcmurry TJ, et al. An effective chelating agent for labeling of monoclonal-antibody with Bi-2 12 for α-particle mediated radioimmunotherapy. J Chem Soc Chem Commun 1991;17: 1169-70.
24. Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A Rapid, Single-Vessel Method for Preparation of Clinical Grade Ligand Conjugated Monoclonal-Antibodies. Nucl Med Biol 1995;22:387-90.
25. Pippin CG, Parker TA, Mcmurry TJ, Brechbiel MW. Spectrophotometric method for the determination of a bifunctional Dtpa ligand in Dtpa monoclonal-antibody conjugates. Bioconjug Chem 1992;3:342-5.
26. McDevitt MR, Finn RD, Sgouros G, Ma DS, Scheinberg DA. An Ac-225/Bi-213 generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isot 1999;50:895-904.
27. Dahle J, Borrebaek J, Jonasdottir TJ, et al. Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate. Blood 2007;110:2049-56.
28. Jurcic JG, McDevitt MR, Pandit-Taskar N, et al. α-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225. Cancer Biother Radiopharm 2006;21:396.
29. Mulford DA, Pandit-Taskar N, McDevitt MR, et al. Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML). Blood 2004;104:496A.
30. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63: 5084-90.
31. Lee YTNM. Breast-carcinoma-pattern of metastasis at autopsy. J Surg Oncol 1983;23:175-80.
32. Charlton DE, Turner MS. Use of chord lengths through the nucleus to simulate the survival of mammalian cells exposed to high LET α-radiation. Int J Radiat Biol 1996;69:213-7.
33. Ballangrud AM, Yang WH, Palm S, et al. α-Particle emitting atomic generator (Actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res 2004;10:4489-97.